title: Uveitic macular oedema after treatment with vemurafenib.
authors: Department of Ophthalmology, BioCruces Health Research Institute, Cruces University Hospital, University of the Basque Country, Barakaldo, Spain.
authors: Alex
authors: A
authors: Fonollosa
authors: Institut Clínic d'Oftalmologia, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain.
authors: Marina
authors: M
authors: Mesquida
authors: Institut Clínic d'Oftalmologia, Hospital Clinic de Barcelona, University of Barcelona, Barcelona, Spain.
authors: Alfredo
authors: A
authors: Adan
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage; D004343:Drug Implants; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects*; D041623:Tomography, Optical Coherence; D014222:Triamcinolone Acetonide / Q000627:therapeutic use; D014605:Uveitis / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D000077484:Vemurafenib; D014792:Visual Acuity
chemical_list: D000970:Antineoplastic Agents; D004343:Drug Implants; D005938:Glucocorticoids; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; D003907:Dexamethasone; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D014222:Triamcinolone Acetonide; D011241:Prednisone